{"nct_id":"NCT05256290","title":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-03","start_date":"2022-03-31","start_date_type":"ACTUAL","primary_completion_date":"2025-07","primary_completion_date_type":"ESTIMATED","completion_date":"2026-06","completion_date_type":"ESTIMATED","phases":["PHASE1","PHASE2"],"tickers":["BDTX"]}